Literature DB >> 16327702

[Adult-onset Still disease with hemophagocytic syndrome treated with cyclosporine].

M Hamidou1, D Boutoille, A Masseau, R Garand, F Raffi.   

Abstract

INTRODUCTION: Adult-onset Still disease can have severe manifestations, the treatment of which is not yet codified. CASE: The authors report a case of life-threatening adult-onset Still disease with hemophagocytic syndrome, which improved dramatically with cyclosporin A. Despite the presence of severe pancytopenia, adult-onset Still disease is suggested by the combination of sore throat, myalgia, rash, hepatitis, high serum ferritin, low glycosylated ferritin, and negative etiologic findings. DISCUSSION: Still disease may be present in patients with febrile pancytopenia, and cyclosporine may be a useful treatment after corticosteroid failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16327702     DOI: 10.1016/s0755-4982(05)84239-3

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Reactive haemophagocytic syndrome in a patient with adult-onset Still's disease: beta-lactams as trigger?

Authors:  F Mearelli; P Vinci; M Gigli; C Casarsa; G Biolo
Journal:  Infection       Date:  2013-11-10       Impact factor: 3.553

Review 2.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

3.  Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review.

Authors:  Antoine Néel; Anaïs Wahbi; Benoit Tessoulin; Julien Boileau; Dorothée Carpentier; Olivier Decaux; Laurence Fardet; Guillaume Geri; Pascal Godmer; Cécile Goujard; Hervé Maisonneuve; Arnaud Mari; Jacques Pouchot; Jean-Marc Ziza; Cédric Bretonnière; Mohamed Hamidou
Journal:  Crit Care       Date:  2018-04-11       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.